Ratings by Morgan Stanley (Matthew Harrison)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/30/2026 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2026 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 2/2/2026 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 12/3/2025 | Regeneron Pharma | REGN | Downgrade | Equalweight (Overweight) |
750.11 (613.46) |
-18.22% | Details | |
| 11/17/2025 | Alector Inc. | ALEC | Maintain | Underweight (N/A) |
|
Details | ||
| 11/12/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/31/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 10/29/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/10/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 6/16/2025 | Sarepta Therapeutics | SRPT | Downgrade | Equalweight (Overweight) |
36.18 (15.42) |
-57.38% | Details | |
| 6/2/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/30/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2025 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2025 | Tenaya Therapeutics Inc | TNYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 2/4/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2025 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2024 | Alector Inc. | ALEC | Downgrade | Underweight (Equalweight) |
3.96 (1.60) |
-59.6% | Details | |
| 11/8/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2024 | Editas Medicine | EDIT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/12/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/26/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Atea Pharmaceuticals | AVIR | Upgrade | Equalweight (Underweight) |
3.37 (4.50) |
33.53% | Details | |
| 8/9/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Equalweight (Overweight) |
8.39 (3.69) |
-56.02% | Details | |
| 6/10/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/28/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2024 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2024 | Tenaya Therapeutics Inc | TNYA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | Editas Medicine | EDIT | Upgrade | Equalweight (Underweight) |
5.68 (2.54) |
-55.28% | Details | |
| 5/8/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2024 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/2/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/26/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 4/25/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 4/24/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/9/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 4/9/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2024 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Equalweight (Overweight) |
10.64 (21.55) |
102.54% | Details | |
| 3/13/2024 | Regeneron Pharma | REGN | Maintain | (N/A) |
|
Details | ||
| 3/13/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2024 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/20/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2024 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 2/8/2024 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/5/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 12/22/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/29/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/28/2023 | argenx SE | ARGX | Maintain | Overweight () |
|
Details | ||
| 11/15/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2023 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2023 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 10/26/2023 | Centessa Pharmaceuticals | CNTA | Upgrade | Equalweight (Underweight) |
6.64 (15.71) |
136.6% | Details | |
| 10/17/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 10/11/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/5/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2023 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2023 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Tenaya Therapeutics Inc | TNYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/4/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/4/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/3/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/3/2023 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 7/28/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2023 | Legend Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2023 | 2Seventy Bio Inc. | TSVT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2023 | ADC Therapeutics | ADCT | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/3/2023 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/3/2023 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/26/2023 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/16/2023 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2023 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 4/25/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2023 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
| 3/30/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/28/2023 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/27/2023 | Vigil Neuroscience Inc | VIGL | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/17/2023 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/15/2023 | Seagen | SGEN | Downgrade | Equalweight (Overweight) |
197.65 (228.74) |
15.73% | Details | |
| 3/10/2023 | Fulcrum Therapeutics | FULC | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/3/2023 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
| 3/3/2023 | Alector Inc. | ALEC | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/1/2023 | Genmab A/S | GMAB | Maintain | Underweight (N/A) |
|
Details | ||
| 3/1/2023 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Sarepta Therapeutics | SRPT | Upgrade | Overweight (Equalweight) |
118.13 (36.18) |
-69.37% | Details | |
| 2/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Fulcrum Therapeutics | FULC | Downgrade | Equalweight (Overweight) |
5.66 (3.56) |
-37.1% | Details | |
| 2/27/2023 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/24/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/23/2023 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2023 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Taysha Gene Therapies | TSHA | Downgrade | Equalweight (Overweight) |
1.89 (5.95) |
214.81% | Details | |
| 1/5/2023 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/5/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
| 11/18/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
| 11/14/2022 | Prime Medicine | PRME | New Coverage | Equalweight (N/A) |
21.12 (2.84) |
-86.55% | Details | |
| 11/14/2022 | Lyell Immunopharma | LYEL | Downgrade | Equalweight (Overweight) |
4.96 (13.80) |
178.23% | Details | |
| 11/4/2022 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 10/27/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/18/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
| 10/13/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2022 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2022 | Amgen | AMGN | Upgrade | Overweight (Equalweight) |
232.15 (354.60) |
52.75% | Details | |
| 9/27/2022 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2022 | Galapagos NV | GLPG | Downgrade | Equalweight (Overweight) |
48.24 (27.73) |
-42.52% | Details | |
| 9/9/2022 | Alector Inc. | ALEC | Downgrade | Equalweight (Overweight) |
10.72 (3.96) |
-63.06% | Details | |
| 9/9/2022 | ADC Therapeutics | ADCT | Downgrade | Equalweight (Overweight) |
6.16 (1.05) |
-82.95% | Details | |
| 9/9/2022 | Regeneron Pharma | REGN | Upgrade | Overweight (Equalweight) |
596.44 (750.11) |
25.76% | Details | |
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/6/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/23/2022 | Pharvaris B.V. | PHVS | Downgrade | Equalweight (Overweight) |
18.49 (32.55) |
76.04% | Details | |
| 8/22/2022 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2022 | Centessa Pharmaceuticals | CNTA | Downgrade | Underweight (Overweight) |
4.75 (39.72) |
736.21% | Details | |
| 8/8/2022 | Royalty Pharma | RPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
| 8/8/2022 | Artivion Inc. | AORT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/8/2022 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2022 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/4/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/3/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/26/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/5/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/23/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/22/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/6/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/2/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/24/2022 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2022 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2022 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2022 | Ionis Pharmaceuticals | IONS | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
| 5/4/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2022 | Vertex | VRTX | Upgrade | Equalweight (Underweight) |
273.22 (425.60) |
55.77% | Details | |
| 5/3/2022 | argenx SE | ARGX | Upgrade | Overweight (Equalweight) |
287.32 (909.04) |
216.39% | Details | |
| 5/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 5/2/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/26/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/25/2022 | Alnylam Pharmaceuticals | ALNY | Downgrade | Equalweight (Overweight) |
168.75 (289.09) |
71.31% | Details | |
| 4/25/2022 | BioMarin Pharmaceutical Inc. | BMRN | Upgrade | Overweight (Equalweight) |
80.50 (56.00) |
-30.43% | Details | |
| 4/18/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Inova Technology, Inc. | INVA | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Fulcrum Therapeutics | FULC | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/12/2022 | BioNTech | BNTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2022 | Royalty Pharma | RPRX | Upgrade | Overweight (Equalweight) |
39.74 (33.12) |
-16.66% | Details | |
| 4/6/2022 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/6/2022 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/6/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/6/2022 | Bristol-Myers Squibb Co. | BMY | Downgrade | Underweight (Equalweight) |
73.79 (57.22) |
-22.46% | Details | |
| 4/6/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/5/2022 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2022 | Vaccitech | VACC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2022 | 2Seventy Bio Inc. | TSVT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/22/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/15/2022 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 3/7/2022 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/7/2022 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
| 3/7/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/25/2022 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/24/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/24/2022 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/18/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/15/2022 | argenx SE | ARGX | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/10/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/10/2022 | Seagen | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2022 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/2/2022 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2022 | Vigil Neuroscience Inc | VIGL | New Coverage | Equalweight (N/A) |
14.65 (8.05) |
-45.05% | Details | |
| 1/31/2022 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/31/2022 | Seagen | SGEN | Upgrade | Overweight (Equalweight) |
122.91 (228.74) |
86.1% | Details | |
| 1/31/2022 | Legand Biotech Corp. | LEGN | Upgrade | Overweight (Equalweight) |
35.78 (35.80) |
0.06% | Details | |
| 1/27/2022 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 1/24/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/24/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2022 | bluebird bio | BLUE | Maintain | Underweight (N/A) |
|
Details | ||
| 1/12/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2022 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/11/2022 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2022 | Atea Pharmaceuticals | AVIR | Downgrade | Underweight (Equalweight) |
8.30 (4.50) |
-45.78% | Details | |
| 1/6/2022 | Adagio | ADGI | Downgrade | Underweight (Equalweight) |
6.50 (4.64) |
-28.62% | Details | |
| 1/6/2022 | Bolt Biotherapeutics, Inc. | BOLT | Downgrade | Equalweight (Overweight) |
4.20 (4.92) |
17.14% | Details | |
| 1/6/2022 | Legand Biotech Corp. | LEGN | Downgrade | Equalweight (Overweight) |
46.75 (35.80) |
-23.42% | Details | |
| 1/6/2022 | Gilead Sciences | GILD | Downgrade | Equalweight (Overweight) |
72.21 (124.96) |
73.05% | Details | |
| 12/16/2021 | BioNTech | BNTX | New Coverage | Equalweight (N/A) |
276.77 (90.47) |
-67.31% | Details | |
| 12/14/2021 | Adagio | ADGI | Downgrade | Equalweight (Overweight) |
34.26 (4.64) |
-86.46% | Details | |
| 11/30/2021 | IO Biotech | IOBT | New Coverage | Overweight (N/A) |
7.61 (0.05) |
-99.34% | Details | |
| 11/30/2021 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/29/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/29/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/29/2021 | Adagio | ADGI | Upgrade | Overweight (Equalweight) |
18.73 (34.26) |
82.92% | Details | |
| 11/23/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/22/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/17/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2021 | 2Seventy Bio Inc. | TSVT | New Coverage | Overweight (N/A) |
33.62 (5.00) |
-85.13% | Details | |
| 11/8/2021 | bluebird bio | BLUE | Downgrade | Underweight (Equalweight) |
13.14 (4.97) |
-62.18% | Details | |
| 11/8/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/29/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2021 | Atea Pharmaceuticals | AVIR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/19/2021 | Freeline | FRLN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/19/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/19/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Vertex | VRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 10/12/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Amgen | AMGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/5/2021 | Atea Pharmaceuticals | AVIR | Downgrade | Equalweight (Overweight) |
42.01 (4.50) |
-89.29% | Details | |
| 9/14/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/7/2021 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/7/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/7/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/7/2021 | argenx SE | ARGX | Downgrade | Equalweight (Overweight) |
349.07 (909.04) |
160.42% | Details | |
| 9/7/2021 | Vertex | VRTX | Downgrade | Underweight (Equalweight) |
199.22 (445.92) |
123.83% | Details | |
| 9/7/2021 | Merck | MRK | Downgrade | Equalweight (Overweight) |
77.12 (121.02) |
56.92% | Details | |
| 9/7/2021 | Johnson & Johnson | JNJ | Downgrade | Equalweight (Overweight) |
174.93 (221.49) |
26.62% | Details | |
| 9/7/2021 | Genmab A/S | GMAB | Downgrade | Underweight (Equalweight) |
48.71 (27.80) |
-42.93% | Details | |
| 9/7/2021 | Amgen | AMGN | Downgrade | Equalweight (Overweight) |
225.96 (232.15) |
2.74% | Details | |
| 8/31/2021 | Adagio | ADGI | New Coverage | Equalweight (N/A) |
30.38 (4.64) |
-84.73% | Details | |
| 8/27/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/24/2021 | Tenaya Therapeutics Inc | TNYA | New Coverage | Overweight (N/A) |
22.67 (0.73) |
-96.78% | Details | |
| 8/20/2021 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2021 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/16/2021 | Royalty Pharma | RPRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/16/2021 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/16/2021 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2021 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/11/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/11/2021 | Imara Inc. | IMRA | Downgrade | Equalweight (Overweight) |
5.90 (17.05) |
188.98% | Details | |
| 8/11/2021 | Fulcrum Therapeutics | FULC | Upgrade | Overweight (Equalweight) |
8.33 (3.56) |
-57.26% | Details | |
| 7/29/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2021 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/23/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Sigilon Therapeutics | SGTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/16/2021 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/16/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/16/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/16/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Alector Inc. | ALEC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Adagene Inc | ADAG | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | ADC Therapeutics | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2021 | Lyell Immunopharma | LYEL | New Coverage | Overweight (N/A) |
15.25 (13.80) |
-9.51% | Details | |
| 6/22/2021 | Centessa Pharmaceuticals | CNTA | New Coverage | Overweight (N/A) |
24.91 (39.72) |
59.45% | Details | |
| 6/18/2021 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
13.49 (44.96) |
233.28% | Details | |
| 6/11/2021 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/10/2021 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/25/2021 | Vaccitech | VACC | New Coverage | Overweight (N/A) |
14.58 (5.00) |
-65.71% | Details | |
| 5/18/2021 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/18/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/18/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/11/2021 | Galapagos NV | GLPG | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/10/2021 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/10/2021 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2021 | Editas Medicine | EDIT | Maintain | Underweight (N/A) |
|
Details | ||
| 5/10/2021 | ADC Technologies | ADCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 4/30/2021 | Vertex | VRTX | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 4/30/2021 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/13/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2021 | Fusion Pharmaceuticals | FUSN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2021 | Freeline | FRLN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2021 | Atea Pharmaceuticals | AVIR | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/29/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/26/2021 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2021 | Akero Therapeutics | AKRO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/22/2021 | ADC Technologies | ADCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/11/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/11/2021 | Galapagos NV | GLPG | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Taysha Gene Therapies | TSHA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Kodiak Sciences Inc. | KOD | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/8/2021 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/8/2021 | Imara Inc. | IMRA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Fulcrum Therapeutics | FULC | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/8/2021 | Adagene Inc | ADAG | New Coverage | Overweight (N/A) |
22.99 (3.60) |
-84.34% | Details | |
| 3/5/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2021 | Pharvaris B.V. | PHVS | New Coverage | Overweight (N/A) |
39.23 (32.55) |
-17.03% | Details | |
| 3/2/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/2/2021 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2021 | Editas Medicine | EDIT | Maintain | Underweight (Underweight) |
|
Details | ||
| 3/2/2021 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Overweight (N/A) |
26.70 (4.92) |
-81.57% | Details | |
| 3/2/2021 | bluebird bio | BLUE | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/26/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/25/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/24/2021 | Huntington Bancshares | HBAN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/18/2021 | Moderna | MRNA | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/17/2021 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2021 | Seagen | SGEN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/8/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/5/2021 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2021 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/2/2021 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/26/2021 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/21/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/19/2021 | Galapagos NV | GLPG | Maintain | Overweight (Equalweight) |
|
Details | ||
| 1/19/2021 | BeiGene, Ltd. | BGNE | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/19/2021 | Amgen | AMGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/19/2021 | Vertex | VRTX | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Regenxbio Inc. | RGNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/19/2021 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Regeneron Pharma | REGN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Biogen | BIIB | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/19/2021 | Seagen | SGEN | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Genmab A/S | GMAB | Downgrade | Equalweight (Overweight) |
44.12 (25.17) |
-42.95% | Details | |
| 1/19/2021 | Gilead Sciences | GILD | Upgrade | Overweight (Equalweight) |
62.40 (124.96) |
100.26% | Details | |
| 1/19/2021 | Silicon Labs | SLAB | New Coverage | Equalweight (N/A) |
135.45 (218.76) |
61.51% | Details | |
| 1/19/2021 | Editas Medicine | EDIT | Downgrade | Underweight (Equalweight) |
75.92 (2.54) |
-96.65% | Details | |
| 1/8/2021 | Sarepta Therapeutics | SRPT | Downgrade | Equalweight (Overweight) |
166.45 (15.42) |
-90.74% | Details | |
| 12/30/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Sigilon Therapeutics | SGTX | New Coverage | Equalweight (N/A) |
41.20 (22.47) |
-45.46% | Details | |
| 12/24/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/16/2020 | Moderna | MRNA | Downgrade | Equalweight (Overweight) |
155.07 (51.51) |
-66.78% | Details | |
| 12/11/2020 | Gilead Sciences | GILD | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/4/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/1/2020 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/16/2020 | Sage Therapeutics | SAGE | Downgrade | Equalweight (Overweight) |
78.00 (44.07) |
-43.5% | Details | |
| 11/16/2020 | Kodiak Sciences Inc. | KOD | Downgrade | Equalweight (Overweight) |
122.63 (34.87) |
-71.56% | Details | |
| 11/12/2020 | Vertex | VRTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2020 | Zentalis Pharmaceuticals | ZNTL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | Evelo Biosciences Inc | EVLO | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2020 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2020 | Gilead Sciences | GILD | New Coverage | Equalweight (N/A) |
58.15 (124.96) |
114.89% | Details | |
| 10/22/2020 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Zentalis Pharmaceuticals | ZNTL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Allovir Inc. | ALVR | New Coverage | Overweight (N/A) |
30.85 (20.92) |
-32.19% | Details | |
| 8/21/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/21/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/12/2020 | Fulcrrum Therapeutics | FULC | Downgrade | Equalweight (Overweight) |
17.12 (3.56) |
-79.21% | Details | |
| 8/10/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2020 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/27/2020 | Biogen | BIIB | Upgrade | Overweight (Equalweight) |
278.51 (183.47) |
-34.12% | Details | |
| 7/15/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2020 | Kaleido Biosciences Inc. | KLDO | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2020 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 7/15/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 7/9/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2020 | BioMarin Pharmaceutical Inc. | BMRN | Downgrade | Equalweight (Overweight) |
127.71 (56.00) |
-56.15% | Details | |
| 7/8/2020 | Vertex | VRTX | Downgrade | Equalweight (Overweight) |
291.31 (445.92) |
53.07% | Details | |
| 6/30/2020 | Legend Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
40.03 (35.80) |
-10.57% | Details | |
| 5/28/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/28/2020 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 5/27/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2020 | Kaleido Biosciences Inc. | KLDO | Downgrade | Equalweight (Overweight) |
6.45 (0.00) |
-100% | Details | |
| 5/21/2020 | Evelo Biosciences Inc | EVLO | Downgrade | Equalweight (Overweight) |
4.32 (0.00) |
-100% | Details | |
| 5/20/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/7/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/7/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2020 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Overweight (N/A) |
30.50 (8.39) |
-72.49% | Details | |
| 4/23/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 4/7/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/3/2020 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | Immunomedics | IMMU | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/3/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/3/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | Forty Seven Inc. | FTSV | Downgrade | Equalweight (Overweight) |
58.00 (95.51) |
64.67% | Details | |
| 2/26/2020 | Galapagos NV | GLPG | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/26/2020 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/18/2020 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/7/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 2/4/2020 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 1/31/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 1/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/17/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/17/2020 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/17/2020 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/17/2020 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 1/17/2020 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2020 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/17/2020 | BeiGene, Ltd. | BGNE | New Coverage | Overweight (N/A) |
167.85 (205.75) |
22.58% | Details | |
| 12/24/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/17/2019 | Amgen | AMGN | New Coverage | Overweight (N/A) |
243.20 (354.60) |
45.81% | Details | |
| 12/17/2019 | Alexion Pharmaceuticals | ALXN | Downgrade | Equalweight (Overweight) |
110.42 (182.01) |
64.83% | Details | |
| 12/10/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2019 | Seattle Genetics | SGEN | New Coverage | Equalweight (N/A) |
117.50 (228.74) |
94.67% | Details | |
| 12/6/2019 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2019 | Cabaletta Bio | CABA | New Coverage | Overweight (N/A) |
14.00 (12.74) |
-9% | Details | |
| 11/11/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2019 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2019 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/1/2019 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 10/11/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2019 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2019 | Biogen | BIIB | Maintain | Underweight (N/A) |
|
Details | ||
| 10/11/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2019 | Galapagos NV | GLPG | New Coverage | Overweight (N/A) |
162.04 (27.73) |
-82.89% | Details | |
| 9/6/2019 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2019 | Incyte | INCY | New Coverage | Equalweight (N/A) |
80.06 (108.38) |
35.37% | Details | |
| 8/12/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2019 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2019 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2019 | BeiGene, Ltd. | BGNE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2019 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2019 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/5/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/1/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2019 | Alexion Pharmaceuticals | ALXn | Maintain | Overweight (N/A) |
|
Details | ||
| 4/9/2019 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Equalweight (Overweight) |
50.19 (36.45) |
-27.38% | Details | |
| 3/4/2019 | Portola Pharmaceuticals | PTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2019 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/25/2019 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2019 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2019 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/8/2019 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/30/2019 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2019 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/22/2019 | Immunomedics | IMMU | Downgrade | Equalweight (Overweight) |
13.31 (87.86) |
560.11% | Details | |
| 1/4/2019 | argenx SE | ARGX | New Coverage | Overweight (N/A) |
98.85 (909.04) |
819.62% | Details | |
| 1/2/2019 | Moderna | MRNA | New Coverage | Overweight (N/A) |
15.27 (51.51) |
237.33% | Details | |
| 12/20/2018 | DBV Technologies S.A | DBVT | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/7/2018 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2018 | Galapagos NV | GLPG | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2018 | bluebird bio | BLUE | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2018 | Immunomedics | IMMU | New Coverage | Overweight (N/A) |
24.03 (13.31) |
-44.61% | Details | |
| 11/2/2018 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2018 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2018 | Kodiak Sciences Inc. | KOD | New Coverage | Overweight (N/A) |
9.56 (34.87) |
264.75% | Details | |
| 10/26/2018 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2018 | Biogen | BIIB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Regeneron Pharma | REGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2018 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2018 | Loxo Oncology | LOXO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Global Blood Therapeutics | GBT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2018 | Forty Seven Inc. | FTSV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Evelo Biosciences Inc | EVLO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2018 | DBV Technologies S.A | DBVT | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/10/2018 | Voyager Therapeutics | VYGR | New Coverage | Equalweight (Overweight) |
19.56 (3.59) |
-81.65% | Details | |
| 8/13/2018 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/13/2018 | Rubius | RUBY | New Coverage | Overweight (N/A) |
21.93 (0.08) |
-99.64% | Details |
